Pharmacy Daily | Rheumatoid arthritis can affect your eyes

RHEUMATOID arthritis affects 1% of the Australian population. Ocular complications include scleritis, episcleritis and retinal vasculitis, while a particular concern is dry eye which can become quite severe. If severe dry eye is not managed appropriately, deterioration of vision can occur in the long term. Latest evidence suggests that dry eye associated with rheumatoid arthritis arises from ocular surface inflammation that can further compromise tear secretion and cause ocular surface disease and symptoms. Anti-inflammatory therapy is a reasonable consideration for patients using artificial tears who have clinically detectable ocular surface disease, particularly if inflammatory signs are present. Optometrists have been prescribing topical ocular medicines since 2000 and practitioners registered with therapeutic endorsement can prescribe Schedule 4 medicines. Initiating a relationship with the optometrist means patients will likely receive regular monitoring, and ongoing eye care that includes screening for other conditions associated with rheumatoid arthritis. Pharmacists and optometrists can help each other by keeping informed of professional developments and expertise. This, in turn, will strengthen collaborative health management and produce optimal outcomes.   This week’s contributor is Giuliana Baggoley, Clinical Policy Adviser, Optometrists Association Australia and presenter at PSA NSW’s Annual Therapeutic Update.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 04 Feb 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Feb 13